EXELIXIS, INC. shareholders approved Approval of the 2017 Plan at the 2026-05-26 meeting.
“3. Approval of the 2017 Plan: Exelixis stockholders approved the 2017 Plan. FOR AGAINST ABSTAIN BROKER NON-VOTES 196,926,657 9,343,837 319,812 22,436,080”
Shareholder Votes
Results of shareholder votes disclosed under 8-K Item 5.07.
EXELIXIS, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-26 meeting.
“2. Ratification of Ernst & Young LLP as Exelixis’ independent registered public accounting firm: Exelixis stockholders ratified the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 1, 2027. FOR AGAINST ABSTAIN BROKER NON-VOTES 222,343,120 6,485,691 197,575 —”
EXELIXIS, INC. shareholders approved Election of 11 directors at the 2026-05-26 meeting.
“1. Election of Directors: Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2027, and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal: FOR AGAINST ABSTAIN BROKER NON-VOTES Mary C. Beckerle, Ph.D. 204,854,581 1,538,523 197,202 22,436,080 S. Gail Eckhardt, M.D. 205,409,482 1,022,879 157,945 22,436,080 Maria C. Freire, Ph.D. 180,367,648 26,067,310 155,348 22,436,080 Tomas J. Heyman 200,508,205 5,902,008 180,093 22,436,080 David E. Johnson 205,319,312 1,096,455 174,539 22,436,080 Michael M. Morrissey, Ph.D. 204,731,180 1,692,296 166,830 22,436,080 Robert L. Oliver, Jr. 205,297,039 1,137,865 155,402 22,436,080 Stelios Papadopoulos, Ph.D. 198,500,120 7,922,275 167,911 22,436,080 George Poste, DVM, Ph.D., FRS 204,405,453 2,023,314 161,539 22,436,080 Julie Anne Smith 202,976,810 3,456,942 156,554 22,436,080 Jack L. Wyszomierski 201,891,192 4,536,760 162,354 22,436,080”
Sunshine Biopharma Inc. shareholders approved to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Series C Warrants pursuant to Section 3.8 of the Series C Warrants. at the 2026-05-28 meeting.
“to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Series C Warrants pursuant to Section 3.8 of the Series C Warrants.”
Sunshine Biopharma Inc. shareholders approved to any adjustment to the exercise price or number of shares of common stock underlying the Series C Warrants issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series C Warrants. at the 2026-05-28 meeting.
“to any adjustment to the exercise price or number of shares of common stock underlying the Series C Warrants issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series C Warrants.”
Sunshine Biopharma Inc. shareholders approved to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that at the 2026-05-28 meeting.
“to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that closed on May 19, 2026 (the “Offering”).”
Equillium, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares. at the 2026-05-28 meeting.
“Proposal 4. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 42,687,545 11,570,307 29,477 0”
Equillium, Inc. shareholders approved Ratification of the appointment of the independent registered public accounting firm. at the 2026-05-28 meeting.
“Proposal 3. Ratification of the appointment of the independent registered public accounting firm. The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 54,274,675 5,234 7,420 0”
Equillium, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split. at the 2026-05-28 meeting.
“Proposal 2. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors in its sole discretion. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 52,697,618 1,559,976 29,735 0”
Equillium, Inc. shareholders approved Election of directors. at the 2026-05-28 meeting.
“Proposal 1. Election of directors. The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal. Former director Peter Colabuono was not renominated as a director and his term ended at the Annual Meeting. In connection with the expiration of Mr. Colabuono’s term, the Company reduced the size of the Board of Directors from seven directors to six directors. The final voting results are as follows: Name Votes For Votes Withheld Broker Non- Votes Charles McDermott 36,072,238 10,018,889 8,196,202 Bruce Steel 45,955,052 136,075 8,196,202”
NU SKIN ENTERPRISES, INC. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026 at the 2026-05-28 meeting.
“Ratification of PricewaterhouseCoopers LLP 38,798,633 970,082 65,184 0”
NU SKIN ENTERPRISES, INC. shareholders approved Approval of the Company’s Amended and Restated 2024 Omnibus Incentive Plan at the 2026-05-28 meeting.
“Approval of the Amended and Restated 2024 Omnibus Incentive Plan 24,185,333 10,177,825 40,483 5,430,258”
NU SKIN ENTERPRISES, INC. shareholders approved Advisory approval of the Company’s executive compensation at the 2026-05-28 meeting.
“Advisory Approval of the Company’s Executive Compensation 33,111,458 1,255,101 37,082 5,430,258”
NU SKIN ENTERPRISES, INC. shareholders approved Election of nine directors to serve until their successors are duly elected and qualified at the next annual meeting of stockholders or until their earlier death, resignation or removal at the 2026-05-28 meeting.
“Election of Directors Emma S. Battle 33,948,833 403,121 51,687 5,430,258 Daniel W. Campbell 33,978,430 298,746 126,465 5,430,258 Steven J. Lund 33,854,219 520,147 29,275 5,430,258 Ryan S. Napierski 34,083,028 289,928 30,685 5,430,258 Laura Nathanson 33,593,418 767,205 43,018 5,430,258 Thomas R. Pisano 34,078,549 279,972 45,120 5,430,258 James M. Winett 34,027,452 330,366 45,823 5,430,258 Edwina D. Woodbury 33,953,493 399,800 50,348 5,430,258 Mark A. Zorko 34,036,158 322,233 45,250 5,430,258”
SILGAN HOLDINGS INC shareholders approved Non-binding advisory vote to approve compensation of Named Executive Officers at the 2026-05-26 meeting.
“The non-binding advisory vote to approve the compensation of the Named Executive Officers of the Registrant received the following votes: For 96,755,314 Against 3,231,739 Abstain 20,864 Broker Non-Votes 3,077,133”
SILGAN HOLDINGS INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-26 meeting.
“The proposal to ratify the appointment of Ernst & Young LLP as the Registrant’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For 102,474,220 Against 593,185 Abstain 17,645”
SILGAN HOLDINGS INC shareholders approved Approval of First Amendment to the Silgan Holdings Inc. Second Amended and Restated 2004 Stock Incentive Plan at the 2026-05-26 meeting.
“The proposal to approve the First Amendment to the Silgan Holdings Inc. Second Amended and Restated 2004 Stock Incentive Plan was approved based upon the following votes: For 99,176,056 Against 793,665 Abstain 38,196 Broker Non-Votes 3,077,133”
SILGAN HOLDINGS INC shareholders approved Election of Directors at the 2026-05-26 meeting.
“Each of the three nominees for election to the Board of Directors of the Registrant was elected as a Director of the Registrant, to serve until the Registrant’s annual meeting of stockholders in 2029 and until his or her successor is duly elected and qualified, based upon the following votes: Withhold Broker Nominee For Authority Non-Votes Leigh J. Abramson 87,358,935 12,648,982 3,077,133 Robert B. Lewis 99,604,397 403,520 3,077,133 Niharika Ramdev 98,317,120 1,690,797 3,077,133”
FiscalNote Holdings, Inc. shareholders approved Ratification of RSM US LLP as independent auditor for 2026 at the 2026-05-27 meeting.
“For Against Abstain 28,118,673 224,144 116,794”
FiscalNote Holdings, Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2026-05-27 meeting.
“Every 1 Year Every 2 Years Every 3 Years Abstain Broker Non- Votes 21,450,842 190,597 26,533 69,096 6,722,543”
FiscalNote Holdings, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-05-27 meeting.
“For Against Abstain Broker Non- Votes 21,500,772 173,462 62,834 6,722,543”
FiscalNote Holdings, Inc. shareholders approved Election of two Class I directors: Key Compton and Timothy Hwang at the 2026-05-27 meeting.
“Name of Director Nominee For Withhold Broker Non- Votes Key Compton 21,489,942 247,126 6,722,543 Timothy Hwang 21,484,901 252,167 6,722,543”
El Pollo Loco Holdings, Inc. shareholders approved Shareholder proposal requesting the adoption of a majority voting standard for the election of directors in uncontested elections at the 2026-05-26 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 15,630,362 6,432,820 67,043 4,658,914”
El Pollo Loco Holdings, Inc. shareholders approved Approval of amendments to the El Pollo Loco Holdings, Inc. Equity Incentive Plan at the 2026-05-26 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 21,485,764 638,820 5,641 4,658,914”
El Pollo Loco Holdings, Inc. shareholders approved Non-binding advisory vote regarding the frequency of future advisory votes on named executive officers' compensation at the 2026-05-26 meeting.
““ONE YEAR” “TWO YEARS” “THREE YEARS” Abstentions 20,056,383 6,777 1,999,819 67,246”
El Pollo Loco Holdings, Inc. shareholders approved Non-binding advisory vote regarding approval of the compensation of the Company's named executive officers at the 2026-05-26 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 21,942,592 175,574 12,059 4,658,914”
El Pollo Loco Holdings, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as the independent registered public accounting firm for 2026 at the 2026-05-26 meeting.
“Votes For Votes Against Abstentions 26,723,782 54,103 11,254”
El Pollo Loco Holdings, Inc. shareholders approved Election of two Class III directors at the 2026-05-26 meeting.
“Nominee Votes For Votes Withheld Broker Non-Votes Tana Davila 22,085,229 44,996 4,658,914 Frank Garrido 22,082,786 47,439 4,658,914”
AtlasClear Holdings, Inc. shareholders approved Ratification of the appointment of Haynie & Company as independent registered public accounting firm at the 2026-05-27 meeting.
“The stockholders of the Company approved the proposal to ratify the appointment of Haynie & Company as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026. Votes For Votes Against Abstentions 56,816,612 2,292,692 196,493”
AtlasClear Holdings, Inc. shareholders approved Proposal to amend the Company's 2024 Equity Incentive Plan to increase the number of shares reserved by 15,000,000 at the 2026-05-27 meeting.
“The stockholders of the Company approved the proposal to approve an amendment to the Plan to increase the number of shares of the Company’s common stock reserved for issuance thereunder by 15,000,000. Votes For Votes Against Abstentions Broker Non-Votes 19,515,189 9,025,146 132,069 30,633,393”
AtlasClear Holdings, Inc. shareholders approved Election of six nominees for director at the 2026-05-27 meeting.
“The stockholders of the Company approved the proposal to elect each of the six directors named as nominees in the Proxy Statement, each to serve until the end of the annual general meeting of shareholders to be held in respect of the fiscal year ended June 30, 2027, or as to each, until their respective successors are elected and qualified, or their earlier death, resignation, disqualification or removal. Name Votes For Votes Withheld Broker Non-Votes John Schaible 25,729,484 2,942,920 30,633,393 Craig Ridenhour 25,725,762 2,946,642 30,633,393 Thomas Hammond 26,171,031 2,501,373 30,633,393 Sandip Patel 25,539,106 3,133,298 30,633,393 Robert Keyser 27,187,355 1,485,049 30,633,393 Steven Carlson 26,278,965 2,393,439 30,633,393”
Neumora Therapeutics, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2026-05-27 meeting.
“Proposal 4. The advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of the vote were as follows: For One Year For Two Years For Three Years Abstentions Broker Non-Votes 124,682,414 23,968 7,948,592 39,349 25,026,919”
Neumora Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-27 meeting.
“Proposal 3. The advisory vote on the compensation of the Company’s named executive officers. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 131,998,871 420,917 274,535 25,026,919”
Neumora Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-27 meeting.
“Proposal 2. The ratification of the selection by the audit committee of the board of directors of the Company (the “Board”) of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The results of the vote were as follows: Votes For Votes Against Abstentions 157,623,815 53,613 43,814”
Neumora Therapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting at the 2026-05-27 meeting.
“Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders and until their respective successor is elected and qualified or until their earlier death, resignation, disqualification or removal. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Paul L. Berns 126,617,746 6,076,577 25,026,919 Matthew Fust 125,242,046 7,452,277 25,026,919 David Piacquad 126,878,899 5,815,424 25,026,919”
TENET HEALTHCARE CORP shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accountants at the 2026-05-27 meeting.
“3. The Company’s shareholders approved the ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2026: FOR AGAINST ABSTAIN BROKER NON-VOTES 79,422,386 470,477 29,318 —”
TENET HEALTHCARE CORP shareholders approved Advisory vote on executive compensation at the 2026-05-27 meeting.
“2. The Company’s shareholders approved, on an advisory basis, the Company’s executive compensation: FOR AGAINST ABSTAIN BROKER NON-VOTES 62,554,346 11,817,273 39,895 5,510,667”
TENET HEALTHCARE CORP shareholders approved Election of Directors at the 2026-05-27 meeting.
“1. The Company’s shareholders elected the following directors to serve on the Company’s Board of Directors, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected or qualified, whichever is later, or until the director’s earlier resignation or removal: FOR AGAINST ABSTAIN BROKER NON-VOTES Saumya Sutaria 72,297,676 2,036,933 76,905 5,510,667 J. Robert Kerrey 71,837,362 2,539,818 34,334 5,510,667 Vineeta Agarwala 73,763,259 621,321 26,934 5,510,667 James L. Bierman 73,793,459 550,313 67,742 5,510,667 Roy Blunt 73,768,660 572,299 70,555 5,510,667 Richard W. Fisher 73,759,704 583,669 68,141 5,510,667 Meghan M. FitzGerald 73,162,461 1,222,005 27,048 5,510,667 Cecil D. Haney 73,782,103 549,561 79,850 5,510,667 Christopher S. Lynch 73,771,835 570,200 69,479 5,510,667 Richard J. Mark 73,767,877 574,980 68,657 5,510,667 Tammy Romo 73,149,469 1,233,024 29,021 5,510,667 Nadja Y. West 73,659,093 710,537 41,884 5,510,667”
ACADIA PHARMACEUTICALS INC shareholders approved Approval of amendment to the Plan to increase authorized shares by 5,209,670 shares at the 2026-05-29 meeting.
“the approval of an amendment to the Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the Plan by 5,209,670 shares, which was approved by the following vote: For Against Abstain Broker Non-Votes 147,258,860 3,096,136 93,751 10,356,394”
ACADIA PHARMACEUTICALS INC shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-29 meeting.
“the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote: For Against Abstain 157,409,378 3,319,736 76,027”
ACADIA PHARMACEUTICALS INC shareholders approved Advisory approval of named executive officer compensation at the 2026-05-29 meeting.
“the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote: For Against Abstain Broker Non-Votes 148,265,173 1,911,358 272,216 10,356,394”
ACADIA PHARMACEUTICALS INC shareholders approved Election of three Class I directors at the 2026-05-29 meeting.
“The following three Class I directors were elected by the votes indicated: For Withheld Broker Non-Votes James M. Daly 146,927,745 3,521,002 10,356,394 Edmund P. Harrigan, M.D. 128,460,130 21,988,617 10,356,394 Adora Ndu, Pharm.D., J.D. 134,540,552 15,908,195 10,356,394”
AMERICAN COASTAL INSURANCE Corp shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-12-31 meeting.
“The stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2026.”
AMERICAN COASTAL INSURANCE Corp shareholders approved Election of five Class B directors for a two-year term.
“The Company's 2026 Annual Meeting was held for stockholders to consider and act upon the two proposals listed below.”
Maplebear Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2026-05-22 meeting.
“The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”
Maplebear Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 at the 2026-05-22 meeting.
“The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”
Maplebear Inc. shareholders approved Election of two Class III directors to hold office until the 2029 Annual Meeting of Stockholders at the 2026-05-22 meeting.
“The Company’s stockholders elected each of the two nominees named below as Class III directors to serve until the Company’s 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation, or removal.”
Bandwidth Inc. shareholders approved Approval, on an Advisory Basis, of the Frequency of Future Advisory Votes on the Compensation of the Company’s Named Executive Officers at the 2026-05-28 meeting.
“Proposal 4 — Approval, on an Advisory Basis, of the Frequency of Future Advisory Votes on the Compensation of the Company’s Named Executive Officers. The stockholders approved, on an advisory basis, the frequency with which future advisory votes on the compensation of the Company’s named executive officers will be held. The results of such vote were: Each Year Every Two Years Every Three Years Withheld/Abstain 39,327,229 20,323 1,526,775 60,832”
Bandwidth Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-05-28 meeting.
“Proposal 3 — Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: For Against Withheld/Abstain 30,884,728 10,011,929 38,502”
Bandwidth Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-28 meeting.
“Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were: For Against Withheld/Abstain 43,322,421 153,912 19,504”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.